Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

BDTX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Black Diamond Therapeutics, Inc.NASDAQ: BDTX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $4.26M fell 14.3% year over year, ahead of the -38.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 7.3% from the prior quarter. Over 3 fiscal years it compounded at -16.4% a year.

Context

  • Selling, general & admin amounted to 23.7% of revenue in FY2025.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $7.06M (-57.4%) for the fiscal year ending Dec 2026, a slowdown from the -39.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.26M+7.3% QoQ
Last fiscal yearDec 2025
$16.57M-39.7% YoY
LTMMar 2026
$15.86M-38.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.3%-100.0%-85.7 pp
1 year-39.7%-57.4%-17.7 pp
3-year CAGR-16.4%-16.0%+0.4 pp
5-year CAGR+34.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
16.57M USD
Year-over-year change
-39.7%
4-year CAGR
-13.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How BDTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -38.3% is the lowest of 11, against a peer median of +28.1%.
  • Over three fiscal years its annual growth of -16.4% compares with a peer median of +3.4%.
BDTX Competitors
Selling, General & Admin for BDTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$4.7B USD+29505.3%+3.5%—
ABEOAbeona Therapeutics Inc.LTM Mar 2026$73.88M USD+132.8%+55.6%508.1%
IVAInventiva S.A.FY2025€53.89M EUR+215.2%+51.5%1202.1%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$52.43M USD+32.8%+31.8%102.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$38.28M USD-25.4%-1.1%55.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$36.25M USD-1.5%-0.1%323.5%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$26.89M USD-3.6%-3.6%95.3%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$24.19M USD+23.5%+3.4%41000.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$23.71M USD-4.5%+3.4%10537.3%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$16.97M USD+137.1%+72.2%—
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$15.86M USD-38.3%-16.4%—
Peer median (excluding BDTX) —+28.1%+3.4%415.8%

Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000070M
Cost of Revenue00437K0325K
Gross Profit00(437K)069.68M
Gross Margin————99.5%
Research & Development96.83M64.44M58.91M51.31M33.56M
Selling, General & Admin30.04M28.39M27.11M27.47M16.57M
Operating Expenses126.87M92.83M86.02M78.78M49.81M
Depreciation & Amortization205K508K437K343K325K
EBITDA(125.39M)(90.66M)(82.01M)(69.33M)22.69M
EBITDA Margin————32.4%
Operating Income(126.87M)(92.83M)(86.46M)(78.78M)19.87M
Operating Margin————28.4%
Interest Income3.46M2.03M1.92M2.18M4.06M
Interest Expense00000
Other Income / Expenses1.28M1.66M4.02M9.11M2.5M
Income Before Tax(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Pre-Tax Margin————32.0%
Income Tax Expense00000
Net Income(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Net Margin————32.0%
EPS (Basic)(3.47)(2.52)(1.88)(1.27)0.39
EPS (Diluted)(3.47)(2.52)(1.88)(1.27)0.39
Weighted Avg Shares36.19M36.23M43.95M55.03M56.87M
Weighted Avg Shares (Diluted)36.19M36.23M43.95M55.03M57.56M

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Intrinsic Alpha fair value

Locked

Current Price

$1.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.